The Research & Development to Assets ratio is a measure to compare the effectiveness of R&D expenditures between companies in the same industry. It is calculated as R&D expenditure divided by Total Assets. This is measured on a TTM basis.
Like R&D / Sales, this is a measure of how much is spent on R&D.
It is useful in comparing the effectiveness of R&D expenditures between companies in the same industry.
R&D expense is not always broken out in a company's financials, however, so this value may be n/a in those cases.
Comparisons are not always useful across industries - for example, pharmaceuticals and software companies tend to spend a lot on R&D while consumer product companies spent less.
This is measured on a TTM basis.
| Ticker | Name | R&D / Assets | StockRank™ |
|---|---|---|---|
| LON:OBI | Ondine Biomedical | 155.43% | 11 |
| LON:ALK | Alkemy Capital Investments | 110.00% | 13 |
| LON:FARN | Faron Pharmaceuticals Oy | 92.44% | 28 |
| LON:SCLP | Scancell Holdings | 91.67% | 6 |
| LON:ARS | Asiamet Resources | 77.39% | 14 |